Carisma Therapeutics, Inc. revenue breakdown overview

Carisma Therapeutics, Inc. revenue for the last year amounted to 19.63 M USD, the most of which — 19.63 M USD — came from its highest performing source at the moment, Chimeric Antigen Receptor Macrophage and Monocyte Cell Therapy, the year earlier bringing 14.92 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Carisma Therapeutics, Inc. 19.63 M USD, and the year before that — 14.92 M USD.